Scleroderma Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: March 01, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 1.98 billion |
|
Revenue Forecast in 2030 |
US$ 3.31 billion |
|
CAGR |
5.9% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug Class, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global scleroderma therapeutics market was valued at US$ 1.98 billion in 2021 and is expected to register a revenue CAGR of 5.9% to reach US$ 3.31 billion by 2030.
Scleroderma Therapeutics Market Fundamentals
Scleroderma is a chronic, although rare, autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection. In scleroderma patients, the immune system triggers other cells to produce excessive collagen. This extra collagen is deposited in the skin and organs, which causes hardening and thickening. Scleroderma can affect the gastrointestinal tract, lungs, kidneys, heart, blood vessels, muscles, joints, and skin. However, it typically just affects the skin. In its most extreme manifestations, scleroderma may pose a serious risk to life. Currently, there is no cure for scleroderma. Thus, the treatment focus is on managing and reducing the symptoms. Since scleroderma can show a wide range of symptoms, a variety of strategies are commonly required to treat and control the condition properly.
[547567]
Scleroderma Therapeutics Market Dynamics
The rising prevalence of scleroderma with increased genetic mutation rate is the major driving factor of the scleroderma therapeutics market. The rise in the R&D in the field of scleroderma to develop novel drugs is also playing a significant role in the revenue growth of the scleroderma therapeutics market. Moreover, a promising product pipeline with the availability of a good regulatory framework, increasing awareness regarding scleroderma, rising healthcare expenditure, and the requirement of regular medications for a long period of time in scleroderma patients are propelling the revenue growth in the scleroderma therapeutics market. Furthermore, the change in environmental factors is also triggering scleroderma in some patients, boosting the development of the scleroderma therapeutics market.
However, the side effects related to the management drugs and the high cost of diagnosing scleroderma are the main factors restricting the revenue growth of the scleroderma therapeutics market. Moreover, the continuous failure of clinical trials and lack of awareness in developing countries are also hindering market revenue growth.
Scleroderma Therapeutics Market Ecosystem
The global scleroderma therapeutics market has been analyzed from three perspectives: drug class, indication, and region.
Scleroderma Therapeutics Market by Drug Class
[85675]
Based on drug class, the global scleroderma therapeutics market is segmented into endothelin receptor antagonists, prostacyclin analogues, immunosuppressors, phosphodiesterase 5 inhibitors – PHA, calcium channel blockers, analgesics, and others.
The immunosuppressors segment dominated the global scleroderma therapeutics market with the largest market share in 2021, as it is the first line of medications to manage scleroderma. Currently, there is no curative medication for scleroderma due to its rarity. Thus, immunosuppressants are used, as they prevent the immune response and manage the symptoms of scleroderma. Moreover, several clinical trials are processed to study the effect of immunosuppressants in scleroderma, which propels the growth of the segment. Additionally, rising investments of major players in R&D to develop novel drugs for scleroderma using biologics immunosuppressants are expected to fuel the segment’s growth.
Scleroderma Therapeutics Market by Indication
Based on indication, the global scleroderma therapeutics market is segmented into systemic scleroderma and localized scleroderma.
The systemic scleroderma segment accounted for the largest revenue share of the scleroderma therapeutics market in 2021. The systemic scleroderma segment is further sub-segmented into limited scleroderma and diffuse scleroderma. The large share of the segment is attributed to the rising prevalence of systemic scleroderma. According to the National Organization for Rare Disorders, systemic scleroderma affects between 38 and 341 individuals per million throughout the world. Systemic scleroderma affects internal organs, and thus is often detected at late stages. Therefore, the demand for the early diagnosis and treatment of systemic scleroderma has been increasing, which is boosting segment revenue growth. Moreover, the high cost of the immunosuppressants used for the treatment of systemic scleroderma is also supporting the market revenue growth. Additionally, the growing geriatric population, as systemic scleroderma most often starts at old age, is fueling the requirement for more intensive and rigorous treatment.
Scleroderma Therapeutics Market by Region
Based on the region, the global scleroderma therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global scleroderma therapeutics market in 2021, followed by Europe. The large revenue share of North America is attributed to the rising cases of scleroderma in the region. According to National Scleroderma Foundation, around 300,000 people are affected by scleroderma in the U.S. Moreover, the well-developed healthcare infrastructure with high healthcare expenditure also facilitates greater uptake of scleroderma drugs in the region. Furthermore, the rise in R&Ds with the investments from government organizations for the development of novel drugs is also propelling the regional market revenue growth. Similarly, the presence of the top companies in the region is also anticipated to drive the North America scleroderma therapeutics market in the next few years.
In Europe, approximately 200,000 individuals suffer from scleroderma. Furthermore, the disease is more prevalent in certain European countries, such as the U.K., where the estimated cases of scleroderma are 20 per million individuals. The demand for scleroderma therapeutics is significantly high in the Europe market, due to the high prevalence of the disease, rise in healthcare expenditure, and rapid approval of different therapeutics. The uptake of biologic drugs is also significantly high in Europe’s scleroderma market, supported by favorable reimbursements.
Asia Pacific market is anticipated to grow at the fastest revenue CAGR during the forecast period. The factors driving the Asia Pacific scleroderma therapeutics market include rapidly increasing healthcare expenditure, a growing pool of scleroderma patients, and increasing awareness about scleroderma among patients and healthcare providers. At present, there are estimated 150,000 scleroderma patients in Asia Pacific. The key players operating in the Asia Pacific scleroderma market, including Sanofi, Boehringer Ingelheim, and Pfizer, are offering scleroderma management drugs, such as vasodilators and immunosuppressors. The demand for generic drugs is significantly high in Asia Pacific; however, traction for biologic agents is also observed recently.
Scleroderma Therapeutics Market Competitive Landscape
The prominent players operating in the global scleroderma therapeutics market are:
Tracleer, a drug from Actelion Pharmaceuticals, is among the most commonly prescribed for treating pulmonary arterial hypertension, a common complication of scleroderma. Similarly, Ofev from Boehringer Ingelheim is also used for treating pulmonary fibrosis arising from scleroderma. Bosulif from Pfizer is currently used in some types of leukemia and has shown promising prospects in the treatment of scleroderma. Rituxan from Pfizer is used as an off-label treatment for scleroderma.
Along with the major multinationals, there are also several small players and academic institutions developing novel treatments for scleroderma. One such is Corbus Pharmaceuticals. The company is developing lenabasum, a synthetic cannabinoid that reduces the inflammation and fibrosis manifested from scleroderma. In conclusion, the global scleroderma therapeutics market is highly competitive, with a limited number of market incumbents and several companies increasing their efforts to produce novel treatments.
Scleroderma Therapeutics Market Strategic Developments
The rise in the prevalence of scleroderma with the increase in the R&Ds to develop a novel drug for scleroderma. Moreover, a strong product pipeline is also boosting market revenue growth.
The side effect of management drugs and the high cost of the diagnosis of scleroderma are some of the factors restricting the market revenue growth.
F. Hoffman La-Roche Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Bayer AG, and Celgene Corporation are among the top market players.
The market is estimated to register growth at a revenue CAGR of 5.9% during the forecast period from 2022 to 2030.
Scleroderma is a chronic, although rare, autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Currently, scleroderma does not have a treatment. Instead, the focus of treatment is on managing and reducing the symptoms. Since scleroderma can show a wide range of symptoms, a variety of strategies are frequently required to properly treat and control the condition.
*Insights on financial performance are subject to the availability of information in the public domain